JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib

Table 2

Patient characteristics and JAK2 levels stratified by the presence of complete hematological response groups.

Variable	Complete hematological response
	Present (n = 27)	Absent (n = 13)	p-Value
Age, years (mean ± SD)	42 ± 12	37 ± 8	0.261
Sex, n (%)	—	—	0.895
Male	16 (59.3)	8 (61.5)	—
Female	11 (40.7)	5 (38.5)	—
Spleen size, cm (mean ± SD)	9 ± 3	7 ± 2	0.167
Laboratory parameters, mean ± SD or median (range)
Hemoglobin (g/dL)	9.8 ± 2.5	8.7 ± 2.6	0.208
White blood cells (/μL)	92,000 (20,390–498,000)	142,250 (33,000–344,130)	0.231
Peripheral blood basophils (%)	1 (0–8)	1 (0–7)	0.467
Eosinophils (%)	1 (0–5)	1 (0–4)	0.285
Platelet count (x10^3/μL)	223 (31–1,123)	445 (49–960)	0.153
Peripheral blood blasts (%)	8 (4–19)	8 (2–20)	0.685
Sokal risk groups, n (%)	—	—	0.941
Low (<0.8)	11 (40.7)	6 (46.2)	—
Intermediate (0.8–1.2)	5 (18.6)	2 (15.4)	—
High (>1.2)	11 (40.7)	5 (38.4)	—
Hasford risk groups, n (%)	—	—	0.701
Low (≤780)	7 (26.0)	5 (38.4)	—
Intermediate (781–1,480)	11 (40.7)	4 (30.8)	—
High (>1,480)	9 (33.3)	4 (30.8)	—
EUTOS risk groups, n (%)	—	—	0.100
Low risk (≤87)	27 (100.0)	11 (84.6)	—
High risk (>87)	0 (0.0)	2 (15.4)	—
JAK2 levels before imatinib treatment, median (range)
JAK2 gene (fold changes)	14.90 (0.18–60.53)	44.01 (9.78–100.40)	<0.001
Phosphorylated JAK2 (U/mL)	0.48 (0.03–0.90)	0.80 (0.24–1.34)	0.005
Total JAK2 (pg/mL)	69.92 (11.82–535.27)	427.56 (45.98–2,291.00)	0.002
JAK2 levels after 3 months of imatinib treatment, median (range)
JAK2 gene (fold changes)	0.70 (0.00–8.80)	1.20 (0.10–39.10)	0.271
Phosphorylated JAK2 (U/mL)	0.48 (0.01–1.10)	0.93 (0.24–13.95)	0.009
Total JAK2 (pg/mL)	22.69 (2.92–282.50)	32.16 (5.49–461.89)	0.613